PharmaCyte Biotech Adds Cancer Drug All-Star to Its Scientific Advisory Board
21 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 21, 2015) - In the world of pharmaceuticals, the approval of a new drug is largely a matter of its relative performance rather than an absolute performance. That is,...
PharmaCyte Biotech's Cell-in-a-Box Technology Makes Good Cancer Drugs Better
13 juil. 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
BONITA, CA--(Marketwired - July 13, 2015) - While many biotech companies are working on new oncology drugs, what's often unappreciated about cancer treatments is how a key improvement in the way drugs...
PharmaCyte Biotech's "Factory" of Live Cells Takes Direct Aim at Cancer Tumors Armed With FDA Orphan Drug Status
18 mars 2015 09h00 HE
|
PharmaCyte Biotech, Inc.
NEW YORK, NY--(Marketwired - March 18, 2015) - PharmaCyte Biotech (OTCQB: PMCB) is aiming directly at the problem patients with advanced pancreatic cancer face, an inoperable tumor! PharmaCyte owns...
Nuvilex's Cancer Treatment Obtaining FDA Orphan Drug Status Would Make Company Attractive Big Pharma Target
14 oct. 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - October 14, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has officially introduced its advanced pancreatic cancer treatment to the U.S. Food and Drug Administration (FDA) in an...
Robbins Arroyo LLP is Investigating the Officers and Directors of Celgene Corporation (CELG) on Behalf of Shareholders
26 sept. 2014 18h16 HE
|
Robbins LLP
SAN DIEGO and SUMMIT, N.J., Sept. 26, 2014 (GLOBE NEWSWIRE) -- Shareholder rights law firm Robbins Arroyo LLP is investigating whether certain officers and directors of Celgene Corporation breached...
Nuvilex CEO and COO Discuss Preclinical and Clinical Trials, Orphan Drug Status, Funding and Much More in Interview
04 juin 2014 08h30 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Jun 4, 2014) - Nuvilex, Inc. (OTCQB: NVLX) President and CEO Kenneth Waggoner and COO Dr. Gerald Crabtree addressed a number of topics associated with the company's...
Nuvilex Positioned for Lucrative Deal With Cell-in-a-Box Technology's Diverse Treatments Amid Biotech Frenzy
20 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 20, 2014) - Nuvilex, Inc. (OTCQB: NVLX) is up to much more than most are currently aware of, and it only takes a bit of digging to realize it. The company is clearly...
Nuvilex's Pancreatic Cancer Treatment Continues to Outperform Big Pharma Heading Into Late Phase Trials
07 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 7, 2014) - Nuvilex, Inc.'s (OTCQB: NVLX) advanced pancreatic cancer treatment first outperformed historical data presented by the NYSE's Eli Lilly and its FDA...
Nuvilex, Inc.'s Cell-in-a-Box Treatment Called Magic Bullets of 21st Century by World Renowned Oncologist
05 mai 2014 09h00 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - May 5, 2014) - Nuvilex, Inc. (OTCQB: NVLX) continued to awe investors last week with yet another marquee name that has agreed to work with its pancreatic cancer...
Nuvilex, Inc. Could Obtain FDA Accelerated Approval After Phase 2b Clinical Trial
17 avr. 2014 08h45 HE
|
Nuvilex, Inc.
NEW YORK, NY--(Marketwired - Apr 17, 2014) - Nuvilex, Inc. (OTCQB: NVLX) has once again delivered a major announcement as it advances its pancreatic cancer treatment toward late phase clinical...